Skip to content

    Asarfi Hospital

    543943
    Healthcare·27 May 2026
    Management Summary

    Asarfi Hospital reported strong financial performance for FY26, with consolidated revenue growing 42% YoY to INR 173.5 crores and PAT increasing 58% YoY to INR 16.7 crores. Q4 also showed robust growth in revenue and IPD. The company is focused on strategic expansion, including increasing bed capacity and exploring inorganic growth, while navigating challenges related to government scheme reimbursements and regulatory delays for new services.

    Highlights

    5

    • FY26 consolidated revenue from operations increased by 42% YoY to INR 173.5 crores, up from INR 121 crores in FY25.

    • FY26 consolidated PAT grew by 58% YoY to INR 16.7 crores, with PAT margin improving to 10%.

    • Q4 FY26 consolidated revenue grew by 29% YoY to INR 45.2 crores.

    • ARPOB for the unit improved significantly to INR 23,000.

    • Total surgeries increased by 26% YoY, exceeding 6,300 procedures.

    Concerns

    4

    • Delay in operationalizing the bone marrow transplant unit due to procedural delays in organ transplant policy approval.

    • Proposed merger with another hospital is delayed due to shareholder inheritance issues.

    • Q4 FY26 saw a decrease in cancer patients due to Jharkhand government scheme changes and administrative delays.

    • Ayushman Bharat scheme has small package rates, making realization difficult and putting pressure on cash realization.

    Key financials

    Metrics

    11

    Periods

    2

    Q4 FY26

    4
    • Revenue
      ₹45.2 Cr
      YoY+29.0%
    • EBITDA
      ₹7.7 Cr
    • EBITDA Margin
      17%
    • PAT
      ₹3.9 Cr
      YoY+9%

    FY26

    7
    • Revenue
      ₹173.5 Cr
      YoY+42%
    • EBITDA
      ₹35.3 Cr
      YoY+42%
    • EBITDA Margin
      20%
    • PAT
      ₹16.7 Cr
      YoY+58.0%
    • PAT Margin
      10%

    Capital allocation

    5
    high confidence
    CategoryHeadline
    Capex

    ₹15 crores

    internal accruals

    Debt

    Debt disclosed

    M&A

    Another hospital (unnamed)

    merger · pending regulatory

    M&A

    Unnamed hospitals

    acquisition · announced

    Liquidity

    Cash ₹8 crores

    Sufficient for planned capex and growth without external debt.

    Guidance & targets

    8
    CategoryTargetPriority
    Revenue
    Consolidated Revenue
    INR 260 crores
    		High
    Revenue
    Overall Revenue
    around INR 400 crores
    		High
    Profitability
    PAT Margin
    13% to 15%
    		High
    Profitability
    EBITDA Margin
    at least 22%
    		High
    Profitability
    EBITDA Margin
    23% to 25%
    		High
    Capacity
    Overall Bed Capacity
    500+ beds
    		High
    Capacity
    Cancer Hospital Bed Capacity
    150 beds
    		High
    Capacity
    Overall Bed Capacity
    1,000 beds
    		High

    Bone Marrow Transplant Facility Approval

    within 4-5 months
    CurrentAwaiting regulatory approval due to organ transplant policy issues
    TargetApproval obtained and facility operational

    Why it matters

    Launch of this high-value service is crucial for expanding specialized offerings and revenue streams.

    Sir, it should take another four, five months, because government is very slow and sometime, I feel that their priority is different. Though there are no organ, bone marrow transplant is not going on anywhere in the Jharkhand, but still there is a delay in the process, what we can do. We are trying very hard. We are rather following it up with the minister directly. But things are not moving as desired.

    How to verify

    risks_and_concerns[risk='Procedural delays for bone marrow transplant approval']

    Risks & concerns

    4
    RiskSeverity

    Procedural delays for bone marrow transplant approval

    Organ transplant policy in Jharkhand is not in a good state, causing delays in obtaining permission for the bone marrow transplant facility, despite other preparations being complete. — Management acknowledged

    medium

    Delay in proposed merger due to shareholder issues

    The proposed merger with another hospital is delayed because heirs of deceased shareholders have not inherited their shares, hindering the process. — Management acknowledged

    medium

    Impact of government schemes and administrative delays on cancer patient volume and realization

    Changes in Jharkhand government schemes and administrative delays led to a decrease in cancer patients in Q4. Ayushman Bharat scheme's low package rates also pressure cash realization. — Management acknowledged

    medium

    Political stability affecting government schemes

    Government schemes and payments are somewhat related to political stability, but management does not expect it to impact them significantly. — Management downplayed

    low

    Q&A highlights

    8

    “Basically, in Jharkhand, the organ transplant policy is not in a good state, and we are trying to obtain approval for the organ transplant facility. Other things have been already arranged. Hopefully, we will get that permission very soon and once the permission is there, we can start.”

    Highlights a key regulatory hurdle impacting the launch of a new high-value service, indicating a delay from previous guidance.

    asked by Nipurn Khemka

    3 min read6 chapters

    Detailed Narrative

    01

    Strong Financial Performance in FY26

    Asarfi Hospital delivered a robust financial performance in FY26, with consolidated revenue from operations increasing by 42% year-on-year to INR 173.5 crores, up from INR 121 crores in FY25. EBITDA also grew by 42% to INR 35.3 crores, maintaining a healthy margin of 20%. Profit After Tax (PAT) saw an even stronger growth of 58% year-on-year, reaching INR 16.7 crores, with the PAT margin improving to 10%. This growth was supported by a 46% increase in IPD revenue and a 34% increase in OPD revenue.

    02

    Q4 FY26 Highlights and Operational Metrics

    For the fourth quarter of FY26, the company reported consolidated revenue of INR 45.2 crores, marking a 29% year-on-year growth. EBITDA for the quarter stood at INR 7.7 crores, with an EBITDA margin of 17%, and PAT increased by 9% year-on-year to INR 3.9 crores. Operationally, the Average Revenue Per Occupied Bed (ARPOB) improved significantly to INR 23,000 in FY26, and total surgeries increased by 26% year-on-year to over 6,300 procedures. The cancer hospital's occupancy rate improved to 42% during FY26.

    03

    Strategic Expansion and Capacity Building

    The company is actively pursuing strategic expansion, aiming for an overall bed capacity of 500+ beds and revenue of around INR 400 crores by Vision 2028, with an EBITDA margin target of 23-25%. A key part of this plan is to expand the cancer hospital capacity from 65 beds to 150 beds. Additionally, the company aims to reach 1,000 bed capacity before FY30. Management also confirmed plans for inorganic growth through acquisitions, which are expected to materialize this financial year.

    04

    Capital Allocation and Funding Strategy

    Asarfi Hospital plans to fund its growth primarily through internal accruals, with no current plans to take on additional debt. The capex for increasing bed capacity in the cancer hospital (from 65 to 150 beds) is estimated at INR 2-3 crores. Furthermore, the construction of the Healthcare Management Research Institute is projected to incur capex of INR 8-10 crores in FY27. The total capex for FY27 is expected to be less than INR 15 crores, supported by existing cash and equivalents of INR 8-10 crores.

    05

    Challenges and Regulatory Hurdles

    The company faces challenges, including procedural delays in obtaining approval for its bone marrow transplant facility due to the organ transplant policy in Jharkhand. A proposed merger is also delayed due to shareholder inheritance issues. In Q4, the cancer segment experienced a decrease in patient volume due to changes in Jharkhand government schemes and administrative delays. Management also noted that government schemes like Ayushman Bharat offer small package rates, impacting cash realization and requiring careful expansion strategies.

    06

    Future Outlook and FY27 Targets

    For FY27, Asarfi Hospital is targeting a consolidated revenue of INR 260 crores and a PAT margin of 13-15%. The company also aims to achieve an EBITDA margin of at least 22% in the coming fiscal year. Management expressed confidence in achieving these targets through a focus on case mix optimization, cost management, and expanding its regional reach by engaging with neighboring districts to attract more patients.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.